Movement Alert｜WuXi Biologics Rises 3.7% in Regular Trading, USD 400 Million Buyback Ongoing as CICC Maintains HKD 48 Target Price

Market Focus06-05

On June 5, WuXi Biologics rose 3.7% in regular trading, trading at HKD 33.26/share, with trading volume of HKD 225 million.

On the news front, the company's USD 400 million share buyback plan continues to be executed aggressively. On June 4, the company repurchased approximately 1.5265 million shares at a cost of around HKD 49.65 million, bringing the cumulative year-to-date buyback amount to HKD 250 million. Meanwhile, CICC recently maintained its Outperform rating on WuXi Biologics with a target price of HKD 48, implying approximately 44% upside from the current share price, corresponding to adjusted P/E ratios of 27.8x/23.7x for fiscal years ending in the next two periods.

The broader Life Sciences Tools & Services sector rallied in tandem, with Pharmaron up 4.32% and WuXi AppTec up 3.24%. The company previously disclosed 69 new integrated projects in the first four months, with roughly two-thirds originating from US and European markets, reaffirming full-year revenue growth guidance of 13% to 17%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1126323459?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-05 09:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1126323459","market":"hk","top_or_hot":-1,"title":"Movement Alert｜WuXi Biologics Rises 3.7% in Regular Trading, USD 400 Million Buyback Ongoing as CICC Maintains HKD 48 Target Price","media":"Market Focus","content":"<p><p>On June 5, WuXi Biologics rose 3.7% in regular trading, trading at HKD 33.26/share, with trading volume of HKD 225 million.</p><p>On the news front, the company's USD 400 million share buyback plan continues to be executed aggressively. On June 4, the company repurchased approximately 1.5265 million shares at a cost of around HKD 49.65 million, bringing the cumulative year-to-date buyback amount to HKD 250 million. Meanwhile, CICC recently maintained its Outperform rating on WuXi Biologics with a target price of HKD 48, implying approximately 44% upside from the current share price, corresponding to adjusted P/E ratios of 27.8x/23.7x for fiscal years ending in the next two periods.</p><p>The broader Life Sciences Tools & Services sector rallied in tandem, with Pharmaron up 4.32% and WuXi AppTec up 3.24%. The company previously disclosed 69 new integrated projects in the first four months, with roughly two-thirds originating from US and European markets, reaffirming full-year revenue growth guidance of 13% to 17%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜WuXi Biologics Rises 3.7% in Regular Trading, USD 400 Million Buyback Ongoing as CICC Maintains HKD 48 Target Price</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜WuXi Biologics Rises 3.7% in Regular Trading, USD 400 Million Buyback Ongoing as CICC Maintains HKD 48 Target Price\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-05 09:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 5, WuXi Biologics rose 3.7% in regular trading, trading at HKD 33.26/share, with trading volume of HKD 225 million.</p><p>On the news front, the company's USD 400 million share buyback plan continues to be executed aggressively. On June 4, the company repurchased approximately 1.5265 million shares at a cost of around HKD 49.65 million, bringing the cumulative year-to-date buyback amount to HKD 250 million. Meanwhile, CICC recently maintained its Outperform rating on WuXi Biologics with a target price of HKD 48, implying approximately 44% upside from the current share price, corresponding to adjusted P/E ratios of 27.8x/23.7x for fiscal years ending in the next two periods.</p><p>The broader Life Sciences Tools & Services sector rallied in tandem, with Pharmaron up 4.32% and WuXi AppTec up 3.24%. The company previously disclosed 69 new integrated projects in the first four months, with roughly two-thirds originating from US and European markets, reaffirming full-year revenue growth guidance of 13% to 17%.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02269","symbol_name":"药明生物","start_time":0,"source_url":"","article_id":"1126323459","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1126323459","pubTimestamp":1780624395,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 5, WuXi Biologics rose 3.7% in regular trading, trading at HKD 33.26/share, with trading volume of HKD 225 million.On the news front, the company's USD 400 million share buyback plan...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02269":"药明生物"},"translate_title":"动向提示|药明生物常规交易涨3.7%，4亿美元回购进行中，中金维持48港元目标价","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02269":1},"content_text":"On June 5, WuXi Biologics rose 3.7% in regular trading, trading at HKD 33.26/share, with trading volume of HKD 225 million.On the news front, the company's USD 400 million share buyback plan continues to be executed aggressively. On June 4, the company repurchased approximately 1.5265 million shares at a cost of around HKD 49.65 million, bringing the cumulative year-to-date buyback amount to HKD 250 million. Meanwhile, CICC recently maintained its Outperform rating on WuXi Biologics with a target price of HKD 48, implying approximately 44% upside from the current share price, corresponding to adjusted P/E ratios of 27.8x/23.7x for fiscal years ending in the next two periods.The broader Life Sciences Tools & Services sector rallied in tandem, with Pharmaron up 4.32% and WuXi AppTec up 3.24%. The company previously disclosed 69 new integrated projects in the first four months, with roughly two-thirds originating from US and European markets, reaffirming full-year revenue growth guidance of 13% to 17%.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1126323459","isCrawlerRequest":true}